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DEFINITION OF TERMS 
 
Adjuvant treatment:  Therapy that is given in addition to the primary 
planned treatment, usually refers to surgery followed by chemo- and / or 
radiotherapy. 
Craniospinal radiation:  Whole brain and spinal cord radiation therapy, 
also referred to as craniospinal radiation, is often a radiotherapy technique 
used in more malignant CNS tumours (e.g. medulloblastomas) to help 
reduce the chances of tumour spread. It often results in more adverse 
effects than local radiation and is therefore avoided in children age 3 and 
under. 
Degree of resection:  Referring to the amount of tumour that a surgeon is 
able to remove at surgery. 
Diencephalic syndrome:  A syndrome that develops in patients where 
damage to the hypothalamus may lead to clinical manifestations such as 
weight loss, inability to regulate body temperature or heart rate.  
Dissemination:  Tumour spread beyond the primary site. 
Grade of tumour: The description of a tumour based on how abnormal the 
tumour cells and the tumour tissue look under a microscope. It may be an 
indicator of the aggressiveness of the tumour, how fast it is likely to grow 
and it's tendency to spread and invade surrounding tissues. 
Hydrocephalus: A pathological condition in which there is abnormal 
accumulation of cerebrospinal fluid (CSF) that may lead to enlargement of 
the ventricular system in the brain and may be caused by many disease 
processes. 
Immunohistochemical analysis: A method for demonstrating the 
presence and location of proteins in tissue sections. 
Molecular-targeted therapy: Therapy that targets very specific molecular 
biochemical pathways in cell cycles that causes  tumour growth. 
Multicentred studies: Research studies where multiple hospitals agree to 
treat children similarly, to pool research data. These are often run by co-
operative groups. 
	 vii	
Neurofibromatosis type 1 (NF1): A genetic disorder that is characterized 
by neurocutaneous abnormalities, including café-au-lait spots, skeletal 
dysplasias, and growth of benign and malignant nervous system tumours. 
Nystagmus: Abnormal involuntary eye movements where the eyes move 
rapidly up and down (vertical nystagmus) or from side to side (horizontal 
nystagmus). 
Parinaud’s syndrome: A syndrome that is clustered by abnormalities of 
eye movement and pupil dysfunction. The clinical manifestation usually 
presents as an inability to look upward, and pupils which do not react well 
to light but react better to accommodation.  
Pineal region: An area behind the upper part of the brainstem. Tumours in 
this area may result in Parinaud’s syndrome, blockage with cerebrospinal 
fluid flow and signs of increased intracranial pressure. 
Posterior fossa: A small space in the skull that contains the brainstem, 
cerebellum and fourth ventricle. It is a common location for brain tumours to 
develop, especially in the paediatric population. Tumours in this area of the 
brain often cause headaches, vomiting, imbalance, motor impairment and 
cranial nerve deficits. 
Suprasellar region: An area behind the eyes, near the hormonal centre of 
the brain that includes the pituitary gland, thalamus and hypothalamus. 
Tumours here often present with visual disturbances as well as hormonal 
imbalances. 
Tuberous Sclerosis Complex (TSC): A rare genetic disease that affects 
multiple systems and is caused by defects in the TSC genes that causes 
benign tumours to grow in the brain and on other vital organs such as the 
kidneys, heart, eyes, lungs, and skin. It usually affects the central nervous 
system and patients may present with a multitude of symptoms including 
seizures, developmental delay, behavioural problems, skin abnormalities, 










Brain tumours are the second most common malignancy in children(1) (2), and 
despite some advancements being made over the last 2 decades, patient 
outcomes in general remain poor when compared with other childhood cancers. 
Optimal treatment of children with brain tumours is challenging and expertise 
and resources are not widely available in South Africa. This is important 
because the outcomes of children with brain tumours depend critically on the 
expertise and resources of a multidisciplinary team tasked with their treatment. 
Despite the importance of paediatric brain tumours though, little is known about 
childhood brain tumours in South Africa as limited data have been published 
and there have been no funded studies to support research in this area. In 
addition, we know very little about the resources available across the country 
to treat these children. In international centres of excellence the best outcomes 
are achieved by combining good epidemiological data, strong multidisciplinary 
teams, centralization or regionalization of services, available resources, and a 
research foundation. To start, we need to know more about the patients 




The overall aim of this project was to collect epidemiological data for childhood 
brain tumours at a tertiary paediatric hospital in South Africa with a dedicated 




Study design: A retrospective review of records of patients diagnosed with a 
primary brain tumour and who presented to Red Cross Children’s Hospital 
(RCCH) system from 1 January 1996 to 31 December 2017.  
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Patient selection & data collection: Patients were identified by combining 
databases and admission logs from paediatric neurosurgery, oncology, 
radiotherapy, histopathology and radiology. Data collected included: age at 




A total of 554 paediatric patients with primary brain tumours were identified over 
the study period. Tumours were more common among males (55.4%) and were 
located in the supratentorial compartment in 52%. The median age at diagnosis 
was 5.92 years. The commonest tumours were astrocytomas (n=114 patients; 
20.3%), followed by medulloblastomas (incl. PNETs) (n=107 patients; 19.1%), 
and craniopharyngiomas (n=55; 9.8%). As expected, most patients referred 
and seen at RCCH/GSH were from the expected drainage area in the Western 
Cape (73%), but a significant number of referrals (27%) were from outside the 




Our findings were largely consistent with the published literature in terms of 
histological diagnosis, sex profile and age ranges for children diagnosed with 
brain tumours with some small differences possibly related to referral bias. 
More patients than expected were referred from outside of the province, which 
emphasizes the need for establishing an ongoing tumour database registry and 
co-ordinating patient care across institutions.  
 
A follow-up study to assess patient management and outcomes is of critical 










INTRODUCTION AND AIMS 
 
Brain tumours are the second most common malignancy in children(1, 2), and 
despite some progress being made over the last 2 decades, patient outcomes 
in general remain poor when compared with other childhood cancers. Optimal 
treatment of children with brain tumours is challenging and expertise and 
resources are not widely available in South Africa. This is important because 
the outcomes of children with brain tumours depend critically on the expertise 
and resources of a multidisciplinary team tasked with their treatment. Despite 
the importance of paediatric brain tumours (PBTs) though, little is known about 
childhood brain tumours in South Africa as limited data have been published, 
no data registry for childhood brain tumours exist in South Africa and there have 
been no funded studies to support research in this area. In addition, we know 
little about the resources available across the country to treat these children. In 
international centres of excellence the best outcomes are achieved by 
combining good epidemiological data, strong multidisciplinary teams, 
centralization or regionalization of services, available resources, and a 
research foundation. An important first step in that direction is to collect local 
epidemiological data. 
 
The overall aim was to collect epidemiological data for PBTs at a tertiary 
paediatric hospital complex with a dedicated multidisciplinary team.  
 
The study objective of this project was to collect data on children with brain 
tumours at a regional centre in South Africa (primarily based at Red Cross War 
Memorial Children’s Hospital, affiliated to the University of Cape Town). The 
epidemiological data generated in this MMED will support a second study to 
assess treatment modalities and outcome data for these patients. The ultimate 
aim is to develop further capacity for infrastructure and research in paediatric 






At Red Cross Children’s Hospital (RCCH) there is a multidisciplinary team 
involved in the management of children with brain tumours, supported also by 
services at Groote Schuur Hospital (GSH). The team comprises specialists in 
paediatric imaging, anaesthesia, intensive care, neurosurgery, oncology, 
radiotherapy, endocrine, neuropathology, neuropsychological and 
neurorehabilitation services. There is a multidisciplinary clinic that follows these 
children for many years after diagnosis and management.   
 
It is our responsibility to collect, audit, review and report our data regularly to 
assess trends in PBTs. We then also need to document the different treatment 
modalities used, and how this correlates to patient survival and functional 
outcomes. This is however outside the scope of this MMED project but is 
already planned as part of a follow-up study. The aim of this study was to focus 






















LITERATURE REVIEW AND INTRODUCTION TO PAEDIATRIC BRAIN 
TUMOURS 
 
A broad but summarised overview of paediatric brain tumours (PBTs) will be 
discussed under the following headings: 
 
• Overall epidemiology 
• Presentation 
• Diagnosis 
• Treatment modalities 
• Most common paediatric brain tumours (summarised in table format) 
o Frequency 




This will allow for simple reference and comparison to the study’s findings, 




Brain tumours are by far the most common solid organ malignancy in children 
and the second most common cause of paediatric cancer overall. From data of 
children in the USA, leukaemias account for 30% of paediatric cancers and 
brain tumours 22.3%(1). The most common solid organ malignancy in children 
after brain tumours is neuroblastoma at 7.3%. About 3750 new cases of 
childhood brain tumours are diagnosed in the USA annually and worldwide 
approximately 30,000 to 40,000 annually(3). The average incidence of childhood 




Brain tumours occur with a comparatively similar incidence across different 
regions, with reports from developed countries estimates in children aged 0-15 
years of 35.9 cases per million children in Sweden, 36.1 in Japan, 32.7 in 
Yorkshire, UK, 29.9 in a survey of 59 European cancer registries (with a 
regional rates up to 43.8), and 47.1 in the USA(4).  
 
Data from low- and middle-income countries though, are limited. Of the 
estimated 250 000 children in whom cancer is diagnosed every year world-
wide, approximately 200 000 live in countries with limited resources. In Africa, 
approximately 50 000 new cases of childhood cancer are diagnosed every 
year. The reported frequencies at which different types of cancers occur differ 
between high-income countries (HICs) and low- and middle-income countries 
(LMICs). Indeed, income-based variations have been observed even within the 
same country(5). In India, where there is also an absence of a comprehensive 
population-based registry, they report an incidence of PBTs that ranges from 
0-2.11%(6). 
  
If the incidence in South Africa is estimated from international figures, we would 
expect at least 500 new cases annually if adjusted for population size, and 
possibly more given the greater proportion of children in our population. The 
only published data in peer reviewed literature that we could find to date reflect 
findings from 20-30 years ago: Peacock et al(2) reported 145 children under the 
age of 14 years who presented between 1979 and 1985. Hesseling et al(8) 
reported 100 children with brain tumours nested within 492 children with all 
forms of cancer diagnosed between 1983 and 1993. Unpublished data from the 
Johannesburg area of 252 patients between 1995 and 2005 reported a much 
lower overall 5-year survival than described in the international literature(9). Of 
those for whom there was follow-up, half died, 20% were alive, and 30% were 
presumed to be alive. However, there was a very high 50% loss to follow up 
that suggests actual mortality might be substantially higher.  
 
Data from studies in LMIC are fraught with difficulties and tend to be skewed 
by late presentations (or non-presentation), suboptimal or inadequate 
management, and high rates of loss to follow-up, while incidence in HIC is 
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higher due to several factors, including the increasing numbers of incidentally 
diagnosed tumours from imaging obtained for other reasons. For several 
multifactorial reasons, intracranial tumours in children are less likely to be 
diagnosed in an African setting, presumably because of a failure to present or 
due to lack of diagnostic imaging. In a Nigerian study, intracranial tumours 
accounted for only 2.2% of all diagnosed childhood cancers in a series of 
1325(10) and in a Ghanaian study, they accounted for a mere 5% in a series of 
375 children(11). A Namibian series reported a proportion closer to that seen in 
HICs (19%), but found a population incidence of only 9.3 per million, far lower 
than that reported in those countries(12). 
 
Another challenge in determining and comparing data for this population of 
patients is that there is such heterogeneity in not only the terms “paediatric 
brain tumour”, but also in categorised age groups, diagnostic criteria, treatment 
modalities available, outcome measures as well as the major changes that has 
occurred in all the before mentioned terms over the past nearly 3 decades. The 
most significant of which must include the histopathological, 
immunohistochemical and molecular subtype advancements that have all 
undergone significant changes and advancements. The WHO classification on 
PBTs has been extensively revised from its first edition in 1979 to its latest and 
4th revised edition in 2016, to keep up with the evolution and growth of 
knowledge in this field.  
 
Table 1 below is adapted from a recently published paper in the journal of 
Child's Nervous System by Elhassan et al(3) from Sudan illustrating 
comparisons between various series published from African countries over the 




TABLE 1: Comparison of common paediatric brain tumours between various series from different African countries(3) 
 
Country Years of study n Mean age (years) Age Ranges (years) M:F ST IT AST MED EPD CPG 
Sudan 2000-2015 62 8.8 0-15 1.38 34 58 52 18 3 1.6 
Nigeria 1960-1982 89 NA 0-15 2.0 53 47 51.1 17.6 5.9 11.9 
South 
Africa 
1979-1985 145 NA 0-14 1.16 47 53 24.8 26.2 10.3 8 
Nigeria 1980-1990 75 NA 0-14 0.75 NA NA 40 10 NA 16 
Tunisia 1990-2004 492 8 (median) 0-16 1.01 50.2 49.8 38 16.2 6.9 5.3 
Morocco 2003-2007 542 9.3 0-19 1.08 NA NA 31.6 28.9 10.3 6.6 
Egypt 2005-2008 451 NA 0-14 1.06 46.6 49.7 35 18.8 10 11.3 
Morocco 1991-2009 633 8.36 0-15 1.22 47 48 23.1 22.9 10.4 9 
Uganda 2002-2012 172 6.5 0-19 1.4 62.2 37.8 32.8 8.1 16.3 9.9 
Nigeria 1994-2006 40 9.75 1-15 1.2 40 60 25 25 2.5 12.5 
 
n: number of patients / M:F Male:Female / ST: Supratentorial / IT: Infratentorial / AST: Astrocytoma / MED: Medulloblastoma / EPD: Epedymoma / CPG: Craniopharyngioma 
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Improvements in the therapeutic regimens and survival outcomes of children 
with leukaemia and other childhood cancers, have resulted in brain tumours 
being the leading cause of paediatric cancer-related deaths, as well as the 
tumour-type resulting in the greatest physical, neuro-cognitive and 
psychosocial morbidity(7). Despite the clear importance then of this topic, it is 
surprising that there are such limited published epidemiological or outcome 
data for childhood brain tumours in South Africa, or for the resources available 
to treat affected children. Neither has there been any funded research on 
paediatric brain tumours in South Africa to our knowledge. Due to the lack of a 
national or even regional brain tumour data registry, we know little about the 
incidence and spectrum of paediatric brain tumours in South Africa, their 
presentation, means by which they are treated, the outcome of affected 




Awareness of PBTs in the public sphere in South Africa is low, particularly when 
contrasted with the successes of campaigns for childhood leukaemia. Because 
there is little co-ordination of health services for children with brain tumours, 
with wide variation existing between institutions in terms of expertise and 
resources, children are often treated inadequately. In desperation, and 
sometimes perhaps in ignorance of services available locally, parents may 
even resort to treatment outside the country and continent, occasionally even 
to extreme and unproven methods.  
 
Primary and secondary level clinicians involved in the initial diagnosis are often 
poorly informed, and the diagnosis can be difficult. Most brain tumours often 
present in a non-specific manner, with vague symptoms associated with raised 
intracranial pressure (ICP) or developmental delay or regression. Delays in 
diagnosis are therefore common, as are inappropriate and potentially 
dangerous interventions such as lumbar punctures before imaging is obtained. 
Amongst clinicians involved in the definitive treatment of children with brain 
tumours, expertise and experience vary, as do resources available to achieve 
optimal outcomes. Currently, there are no local protocols or consensus 
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agreements on how best to manage childhood brain tumours on a national 
level.  
 
Children with brain tumours may present in a variety of different ways and at 
different ages with the clinical presentation typifying the complexity of the 
pathology itself. PBTs may produce symptoms based on their location, size, 
and subsequent raised ICP caused by brain shift and/or hydrocephalus (7).  
The tumour may cause direct neurological damage resulting in specific clinical 
localising signs and neurological deficits. Typically midline and infratentorial 
tumours often present with hydrocephalus as obstruction to CSF flow tends to 
occur earlier compared to tumours in other locations . Symptoms are often non-
specific and may include headaches, vomiting, seizures, visual disturbances 
and lethargy. Although other causes of headaches in children are more 
common, a change in headache pattern, an acute onset, or association with 
vomiting are warning signs(7). 
 
Posterior fossa tumours may often present not only with headaches and 
vomiting, but also with clinical features of cerebellar and / or cranial nerve and 
brainstem dysfunction, including imbalance, ataxia, cranial nerve palsies and 
bulbar dysfunction. Tumours in the suprasellar region often present with visual 
disturbances and/or endocrinopathies. Pineal region tumours usually present 
with hydrocephalus or Parinaud's syndrome which includes a clinical syndrome 
of abnormal eye movements, pupils which do not react well to light but react 
better to accommodation, and a downward gaze palsy(7).  
 
Early diagnosis is often challenging, especially in infants and young children. 
For infants, a delay or regression in developmental milestones can be an early 
symptom of a brain tumour, particularly for those with sizable, midline low-grade 
tumours. Clinical signs may be subtle and often missed as visual changes are 
notoriously difficult to diagnose in infants and the presence of headaches 
difficult to establish at a young age. An abnormal increase in head 
circumference is often easier to pick up by serial measurements in head 
circumference and may indicate the presence of hydrocephalus.  Hypothalamic 
/ optic pathway tumours may present with features of diencephalic syndrome 
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often manifested by weight loss despite adequate diet or difficulty regulating 
body temperature. The euphoric elements of this syndrome are absent and 
infants are often excessively irritable. In school-age children, sizable midline or 






In most reports, more than half of brain tumours are infratentorial, a 
compartment that is notorious for hiding pathological changes on scans until 
the tumour is of obvious size or causing hydrocephalus. However, the diagnosis 
of PBTs has greatly improved over the past few decades and has been 
streamlined by the increased accessibility and quality of brain imaging.  
 
Magnetic Resonance Imaging (MRI) has better sensitivity in the detection 
characterization of brain tumours. Other tests such as Positron Emission 
Tomography (PET) scans may be helpful, but are not widely used for diagnostic 
purposes. Very occasionally they are used for determining the aggressiveness 
of the tumour or distinguishing tumour from inflammation. Since brain tumours 
in childhood, especially the embryonal ones, may spread to other sites within 
the nervous system, most patients require an MRI of the entire craniospinal-
axis for appropriate evaluation and staging  prior to surgery or adjuvant therapy. 
Lumbar puncture (LP) may disclose leptomeningeal spread of the tumour not 
seen on MRI. 
 
Histopathological diagnosis 
Tumours of the central nervous system (CNS) are challenging to treat for many 
reasons, even in the best circumstances, in part because there is great variety 
in the anatomical location and histological types. Multiple tumour histologies 
are seen in paediatrics tumours, both benign and malignant. Basic histologic 
subgroups include astrocytic and glial-derived tumours, neural and neuroglial 
tumours, ependymal tumours, ependymal tumours, embryonal or supratentorial 
primitive neuroectodermal tumours (PNETs), malignant rhabdoid tumours such 
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as ATRTs, choroid plexus tumours, pineal parenchymal tumours, germ cell 
tumours, meningeal tumours, pituitary tumours, and haematopoietic, skull or 
dermal-derived tumours. Astrocyte-derived tumours include pilocytic 
astrocytoma, pilomyxoid astrocytoma, pleomorphic xanthastrocytoma, 
subependymal giant cell astrocytoma, fibrillary astrocytoma, anaplastic 
astrocytoma and glioblastoma. Low-grade gliomas (LGGs), consisting of WHO 
I and II tumours, account for approximately 60% of hemispheric tumours in 
children(13), and they occur at an incidence of five per million children per year. 
The mean age of diagnosis is around 6-11 years(13). 
 
While some tumours are benign and curable by complete, or sometimes even 
by near-complete resection (e.g. juvenile pilocytic astrocytomas (JPAs) or 
subependymal giant cell astrocytomas (SEGAs); others are highly malignant 
and likely incurable even with a gross total macroscopic resection (e.g. atypical 
teratoid rhabdoid tumours [ATRT], glioblastoma multiforme [GBM]). 
Additionally, brain tumours occur in different location in the cranium and 
therefore pose different risks to the neurological function of the child and 
suitability for treatment. The location of the tumour affects the surgical 
resectability of the lesion, which in most cases determines the likelihood of a 
cure. Even when tumours are treatable, a location in eloquent regions of the 
brain or brainstem may render the risks of surgery unacceptable for a 
reasonable quality of life, and the surgical procedure itself may be the cause of 
death. A benign JPA is theoretically curable but may occur deep within the 
hostile environment of the brainstem and so pose a mortal threat independent 




It is clear from published data that good outcomes depend on a dedicated 
multidisciplinary team, yet this cannot be achieved easily in the private sector, 
and its availability in the public sector is limited. Several factors affect outcome. 
A high level of suspicion increases the chance that children are imaged 
appropriately. Adequate imaging of PBTs requires a dedicated environment as 
magnetic resonance scans in young children are difficult, if not impossible, 
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without adequate and safe sedation or general anaesthesia. Once the tumour 
is identified on imaging, the most important treatment-related factor in the 
likelihood of affecting success is the extent of surgical resection where possible. 
This depends not only on the tumour, but considerably on the neurosurgeon’s 
training, expertise and infrastructure supporting surgery. Few neurosurgeons in 
the country operate on childhood brain tumours frequently enough to achieve 
and maintain the required expertise. Moreover, the experience of the paediatric 
anaesthesiologist and the availability of dedicated paediatric intensivists are 
essential to secure optimal outcomes. Experienced neuropathologists are 
similarly important. Adjuvant treatment, and indeed further surgical decisions, 
depend on an accurate histopathological diagnosis. Because the definitive 
histological diagnosis of PBTs can be notoriously difficult, and because this has 
a substantial impact on decisions on how best to manage the child, specific 
experience in paediatric neuro-pathology is essential. For example, ATRTs are 
now increasingly recognized as small round blue cell tumours usually occurring 
in the posterior fossa, likely previously confused with medulloblastoma, but 
identified by the lack of expression of hSNF5, the protein encoded by the 
tumour suppressor gene SMARCB1. It has an extremely poor prognosis and 
the distinction from medulloblastoma is critical for management purposes. 
Existing data from African patients do not reflect this entity. 
 
The treatment regimens are tailored to each patient and most often includes a 
combination of surgery, chemotherapy, and radiation therapy, as well as 
management for conditions that develop as consequence to the treatment 
administered, such as endocrinopathies requiring hormone replacements and 
long-term follow up.   
 
Surgery 
For most childhood brain tumours, surgery is a pivotal cornerstone in 
management, not only to confirm the histology of the tumour, but also to resect 
as much tumour as can be safely accomplished. The degree of resection, or 
more specifically the amount of tumour left after surgery (residual tumour), is 
closely related to patient prognosis. Adjuvant therapy is usually not decided on 
until there is histopathological confirmation, with few exceptions such as optic 
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pathway gliomas, germ cell tumours with markers, and radiologically-typical 
DIPGs.  
 
Improvements in anaesthesia, surgical navigation, and intraoperative 
neurophysiology have improved surgical safety and in many cases have 
allowed more aggressive resections without compromising neurological 
function. However, the risk of neurologic injury and dysfunction after brain 
tumour surgery remains a significant problem. These relate to the specific area 
of brain involved, or may be general, including postoperative hydrocephalus, 
bleeding, or infection. A common surgical complication for infratentorial 
tumours is the “posterior fossa mutism syndrome”, also known as the 
“cerebellum mutism syndrome”. In this circumstance, after surgery for a 
posterior fossa tumour (primarily in those with medulloblastomas but also after 
surgery for any type of midline cerebellum tumour), the patient typically has a 
delayed recovery, with poor word output or complete mutism, often 
commencing after a couple of days. The cerebellar mutism syndrome is due to 
disruption of critical pathways from the  dentate nuclei in the cerebellum through 
the upper brainstem and projecting to the thalamus and cerebral cortex(7). This 
mutism is not an isolated finding and may be associated with restlessness or 
irritability, bulbar palsies, supranuclear cranial nerve palsies, hypotonia, and 
cerebellar symptoms. Often cerebellar mutism syndrome is transient and 
clinical improvement may occur over days to weeks, however patients may be 
left with residual speech and balance deficiencies.  
 
Radiotherapy 
Radiotherapy is essential in many forms of childhood brain tumours to treat 
residual tumour post-resection, prevent recurrence, and sometimes palliate, but 
may be limited by the age of the patient and potential injury to the developing 
brain, both for neurocognitive development and the risk of secondary 
malignancies. 
 
Once again, decision-making, planning, mark-up, and delivery for PBTs require 
experience and infrastructure, without which, results are suboptimal. Many 
centres country-wide will not undertake paediatric radiotherapy due to lack of 
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experience and time constraints. Optimal sedation or anaesthesia is frequently 
required, and neuro-cognitive outcome is directly related to optimal techniques.  
 
Chemotherapy 
Chemotherapy has significantly changed outcome for leukaemias, but less so 
for brain tumours, partly because the blood brain barrier (BBB) restricts the 
delivery of certain chemotherapeutic agents.  
 
Increasingly, children are receiving chemotherapy for brain tumours such as 
medulloblastomas, ependymomas, and midline astrocytomas. The decision-
making, regimens, infrastructure and support in this all critical to the successful 
management of these patients. Ideally, all of these children should be followed-
up in a multidisciplinary clinic, given the risk of recurrence and the potential for 
long term neurological, endocrine and neuropsychological complications; 
however, this is rarely available. 
 
Advances  
Recent new advances in treatment modalities and strategies have been 
promising for paediatric brain tumours but are not widely accessible. In surgery, 
recognition of subspecialist expertise, improved imaging and intraoperative 
visualization, and intraoperative neurophysiology have improved the safety of 
surgery and extent of resection achievable, even in critically eloquent areas. 
Radiotherapeutic advances in image fusion techniques, 3D conformal radiation 
therapy, intensity modulated radiotherapy, stereotactic radiosurgery, and 
proton beam therapy have also improved the safety and effectiveness of 
radiotherapy but again are not widely available. While most of the 
chemotherapy regimens use well-established agents, there have been 
improvements with drug delivery techniques such as the use of intra-Omayya 
reservoir interferon therapy for patients with craniopharyngiomas. While 
intensive approaches such as high dose therapy with autologous stem cell 
rescue have not yielded dramatic improvements in the outcomes of high risk 
brain tumours, there is a potential role for biological small molecules and 
monoclonal antibodies, as well as for anti-angiogenic and metronomic 
strategies(14). 
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Certainly one of the most exciting advancements in paediatric neuro-oncology 
research has been in the field of molecular biology. Classification of brain 
tumours has improved; this relies now not only on the histology of tumour cells 
but also increasingly on immunohistochemical markers, cytogenetic analysis 
and molecular subtyping. Recent work on medulloblastomas illustrates this 
principle: it is increasingly clear that the entity of medulloblastomas comprises 
at least 4 distinct subtypes that have epidemiological correlates, therapeutic 
implications and prognostic value. It is expected that identification of these 
subtypes will be required for entry into clinical trials and will eventually guide 
targeted therapeutic decisions in the future. 
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TABLE 2: Summary of some common specific paediatric brain tumour types(13)







1. JPA (Grade I) most
common (discussed
here)
2. Fibrillary (Grade II)
3. Anaplastic(Grade III)
4. GBM(Grade IV)
Most common age in children: 5-10yrs 
M:F ±1:1 
Assoc with NF1 
Location: Cerebellum 60% 
Optic pathway 25-30% 
Surgical resection is first 
option and if gross total 




If GTR can be achieved 
tumour has good 
prognosis with at 5 and 10 
year survival >95% 
BRAF alterations in 
±70% 
Lacks IDH mutations 
and TP53 mutations  
Medulloblastoma 
Most common malignant tumour of 
childhood 
• WNT (least common ±10%)




o Age bimodal <3yrs and >16
o M:F 1:1
o Classic > Desmoplastic
• Group 3 (25%)
o infants and children (rare in
adults)
o M > F (2:1)
o Classic > Large cell anaplastic
• Group 4 (most common; 45%)
o typically children, peak age 10
yrs (rare in infants)
o M:F 3:1
o Classic = Large cell anaplastic
4 molecular subgroups currently 








Surgery +/-  
ChemoRx +/-  
RadioRx 
Prognosis is most strongly 
influenced by molecular 
subtype: 
• WNT: very good
• SHH: infants good,
others intermediate
• group 3: poor
















Craniopharyngioma Approx 4% of PBTs 
Bimodal age distribution: 5-14 yrs and 
45-65 yrs 
M:F ± 1:1 
Two histologic subgroups:  
• Adamantinomatous 
• Papillary (mainly in adult 
group) 
Surgery +/-  
Radiotherapy +/- 
Interferon therapy 
Main predictor of outcome: 
hypothalamic involvement, 
tumour recurrence and 
endocrinologic dysfunction 
Histologically benign 
but behaviour often 
more of a malignant 
course 
Choroid plexus tumours 2-4% of all PBTs 
Main location: lateral ventricles (50-
70%) 
WHO 3 groups:  
• Grade I choroid plexus 
papilloma (CPP) 
• Grade II Atypical CPP 
(ACPP) 
• Grade III choroid plexus 
carcinoma (CPC) 
CPP: GTR of tumour is 
cornerstone of Rx 
CPC: GTR +/- craniospinal 
RadioRx +/- chemoRx 
(adjuvant presurgical 
chemoRx may increase 
chance of GTR) 
CPP: 90% 1-year-survival, 
and 77% 5-year-survival 
 




and Aicardi Syndrome 
Ependymoma Approx 8-12% of all PBTs 
Median age 4-6 yrs 
M>F 
Location: 70% are infratentorial 
Histology 3 groups WHO: 
• Grade I myxopapillary or 
subependymoma 
• Grade II cellular, papillary, 
clear cell or tanycytic 
• Grade III anaplastic 
Current standard of care is 
safe maximal surgical 
resection ± focal RadioRx 
post resection  
Tumour location, grade, 
patient age and initial 
treatment all contribute to 
progression-free survival.  
Median time to recurrence 
is within 2 yrs of Dx in 
±33% of patients 
Most tumours are 
sporadic but 
associations with NF2 
may be seen 
Brainstem glioma 10-20% of PBTs 
Peak age 7-9 yrs 
M:F ± 1:1 
Tumours broadly categorised as 
diffuse infiltrating or focal and 
further categorised on 
anatomical location, i.e. 
Midbrain, Pons, Medulla, 
cervico-medullary 
DIPGs are the most commonly 
occurring brainstem tumour in 
children 
DIPGs are not amenable to 
surgical resection and role 
of biopsy is to confirm 
diagnosis where there is 
doubt. 
RadioRx remains the 
mainstay of Rx strategy ± 
palliative re-irradiation 
proposed at time of tumour 
progression. 
DIPGs have the worst 
prognosis of the brainstem 
tumours with median 
survival of less than 1 year 
from time of Dx 
Still on-going molecular 
biology discoveries 
showing promising 
future areas for 
potential targeted Rx. 
Pineal 
Includes  









Young children (median age 5.5 yrs) 
M:F ± 1:1 
WHO Grade IV tumours, highly 
aggressive 
Treatment is usually multi-
modal with a combination of 
surgery, chemoRx and 
radioRx.  
Despite treatment, the 
prognosis has historically 
been poor, with a 5-year 
survival as low as 10%. 
More recently 5-year 
survival of 58-81% have 
been reported 8,12 with 
median overall survival 











ATRT Present in young children: ±70% dx 
before age 1 yr; 90% dx before age 3yrs 
 
M>F (±1.6:1)  
 
Aggressive rare malignancy ±1-
2% of PBTs 
 
Location: 50-66% infratentorial 
with cerebellum the most 
common site 
 
CSF dissemination present in 
±20% 
 
Depends on age of patient 
but needs multimodal 
approach combining 
maximal safe surgical 
resection, craniospinal 
RadioRx and intensive 
chemoRx 
Clinically AT/RTs have 
much poorer prognosis 
than medulloblastomas, 
with little if any response 
to chemotherapy and 
death usually occurring 






Treatment and long term outcomes depend on many factors, which attest to the 
complexity of treating these patients. Factors such as tumour type, location within 
the brain and surrounding structures, presence of metastatic disease as well as 
the patient's age and general health all contribute heavily towards developing the 
best, most feasible treatment strategy for each individual patient. Table 3 below 
summarises shows survival data for paediatric posterior fossa tumours with 
current best management strategies for some of the most common paediatric 
tumours. Because new treatments and technologies are continually being 
developed, several options may be available at different points in treatment. 
 
TABLE 3: Survival data for paediatric posterior fossa tumours with current 
best management(13) 
 
Tumour Progression-Free Survival 
Rate 
Overall Survival Rate 
Pilocytic astrocytoma >90% at 5 years 85-95% at 10 years 
Medulloblastoma Average-risk MB:  
  85% at 5 years 
High-risk MB: 
  70% at 5 years 
High-risk MB <50% at 5 
years 
Ependymoma 23-45% at 5 years Children:  
  50-60% at 5 years 
Infants:  
  42-55% at 5 years 
AT/RT Without RT: 
  20-30% at 2 years 
With RT: 
  53% at 2 years 
Without RT:  
  53% at 2 years 
With RT: 
  70% at 2 years 
CPP 83% at 5 years 100% at 5 years 
85% at 10 years 
CPC  GTR:  52% 








Study objectives To collect epidemiological data for childhood brain tumours at 
a tertiary paediatric hospital with a dedicated multidisciplinary team. A 
retrospective study was undertaken to collect data of all children with primary 
brain tumours presenting to RCCH and GSH.  
 
Study design Retrospective study: The records of all patients diagnosed with a 
primary brain tumour and who presented to RCCH and GSH between 1 January 
1996 and 31 December 2017 were examined. The patients were primarily based 
at RCCH, which has an upper age limit of 13 years; however, occasional patients 
referred to the multidisciplinary clinic were occasionally older (age range 0-17 
years). All data were captured in an excel-based database, the excel spreadsheet 
developed is attached in the appendix section for reference.  
 
Patient selection & data collection Until this study was undertaken, no single 
comprehensive database for children with paediatric brain tumours treated at 
RCCH and GSH existed. To assemble this database and ensure the most 
accurate and complete database was composed, multiple sources were used to 
develop a comprehensive, accurate list of patients.  
 
This was done by creating 5 databases from multiple diverse sources: 
 
Histology database: This was created by capturing every histology result logged 
in the histology record books and result files from 1 January 1996 - 31 December 
2017 for children that had neurosurgical specimens sent to the lab for diagnosis.  
 
Surgical database: This was accessed from theatre logbooks capturing all 
patients who underwent a neurosurgical procedure.  
 
Neurosurgical ward admissions database (D1 database): All the admissions 
to the paediatric neurosurgical unit from 1 January 2000 - 31 December 2017 (the 
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electronic admission computer system was only introduced in 2000 and all 
admission records prior to 2000 were not obtainable) were scanned for diagnosis 
and folders were reviewed in cases where there were uncertainty of diagnosis. 
The admissions clerk captures all children on an electronic record platform 
(CliniCom) and admissions are typically done in the surgical speciality ward 
(including neurosurgery) under the patients name and diagnosis code (ICD -10). 
Nearly 8000 folders had to be screened to ensure that no patients were missed.  
 
Oncology database (G1): Oncology folders at RCCH were obtained from lists 
compiled of clinic visits as well as cross-referencing with clinician’s databases; 
information was again cross-referenced for accuracy. Patients with brain tumours 
are occasionally referred directly to the oncology team without necessitating 
neurosurgical admission and therefore this database attempted to screen for 
those patients not seen by the neurosurgery team as primary treating doctors.   
 
Combined multidisciplinary clinic at GSH (LE34): This is where paediatric 
patients are seen at a combined clnic involving all disciplines. This list was 
obtained from the oncology clinic clerks. Additionally a similar list for the adult 
neuro-oncology clinic was obtained and screened for children in the system who 
may have have been transferred to the adult neuro-oncology clinic.  
 
Other sources used to cross-reference information included Dr Riedemann's 
database (from the department of radiation-oncology at GSH) on his work done 
on children with medulloblastoma's; as well as the electronic radiology system 
(PACS) for checking information on patients from 2012 (when the electronic 
radiology system was introduced) until 2017. 
 
These databases were combined, cross-referenced and collated into a final  
conglomerate master sheet database that was then analysed and used to report 
on the findings presented in this MMED. Every attempt was made to minimise on 
missing data by combining the various sources and databases described above.  
 
Data collected included: age at diagnosis, sex, province of referral, tumour site 
and diagnosis (including histological diagnosis where biopsy or surgery was 
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performed). As part of a planned follow up study and paper, a detailed analysis 
will be done examining treatment modalities utilised and patient outcomes based 
on the list of patients identified in this MMED.   
 
Demographic information included suburb/town and district of residence if the 
patients were from the Western Cape; or province if the patients where referred 
from outside the Western Cape or country of referral if the patients where 
international referrals. 
 
The admission age for RCCH is usually limited to 0 to 13 years of age. 
Occasionally older patients are treated and appropriate overage consent forms 
were obtained from RCCH to treat these patients and they were not excluded 
from this study. Occasionally patients over that age are referred directly to the 
multidisciplinary clinic. Although the oldest patient in the study was 17 years old, 
patients over the age of 13 were not typical due to the admission criteria of the 
hospital. The focus of the study was primary brain tumours. Therefore, we 
excluded metastatic lesions where the primary tumour was outside the CNS were 
excluded, as well as primary spinal cord tumours (to be examined in a separate 
study). 
 
Other important information that will reported in the follow up study includes 
details of the presentation, initial presentation, treatment delivered, results of 
treatments, complications, and outcome.  
 
The attached excel datasheet (appendix 1) was used for the purpose of this study. 
 
Statistical analysis The study was primarily descriptive. Graphs, charts and 
geographical maps were used to illustrate and describe the data obtained and to 
show various tumour types, ages of patients, gender as well as referral patterns 
from both provincial patterns within the Western Cape and outside of the Western 
Cape.  
 





Retrospective data collection despite best efforts is always incomplete. Missing 
or incomplete data was found to be 1.1% of patients identified but does not include 
the "unknown" patients that were not identified throughout the various sources 
described above. Reasons for missing data are discussed in chapter 5.  
 
Given that we continue to follow patients for many years after their diagnoses, 
missing data have been minimized and every attempt has been made to fill in the 
gaps. Where patients had died, we did not make any attempts to contact the 
family for information. While necessary, retrospective studies are known for these 




Ethical approval was obtained from both the Human Ethics Board of the University 
of Cape Town (HREC REF: 229/2018) as well as the Departmental Research 
Committee (see appendix 2 and 3). All patient records were de-identified to 
maintain anonymity when analysing and publishing results. Patient management 
was in no way affected by the study. 
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Data from 554 patients identified and admitted to the combined paediatric neuro-
oncology service between 1 January 1996 and 31 December 2017 were reviewed 
and are reported here according to:  
• Geographic referral pattern 
• Patient demographics: age and sex 
• Anatomical location of tumour 
• Pathology 
 
Geographic referral pattern 
 
The paediatric neuro-oncology group at RCCH/GSH receives referrals at both 
provincial and national levels; occasionally this extends to other African countries.  
 




























Figure 1 above depicts the overall referral pattern for all the patients referred from 
1996-2017 to the paediatric neuro-oncology group at RCCH/GSH.  
 
As expected, most patients referred and seen at RCCH/GSH were from the 
expected drainage area in the Western Cape (73%); 26% were out of province 
referrals. This is discussed in further detail in chapter 5.  
 
Figure 2 illustrates how the referral pattern over the time period of the study. In 
the last 10 years, the median percentage of cases referred from outside of the 
province was 28.6% compared with 20.7% of cases managed prior to that. Most 
of these out of province referrals (excluding the Eastern Cape) were from the 
private sector. 
 




The maps below illustrate the geographical referral patterns, 1) in South Africa, 



































































MAP 1: Map of South Africa showing number of referrals per province 
 
 







































TABLE 4: Summary of age, sex, referral site, and anatomical location 
 
Variable Number (n) / Percentage (%) 
Age (years) 
    0-3 
    4-9 
    10-13 
    >13 
 
147 / 26.5 
259 / 46.8 
113 / 20.4 
35 / 6.3 
Sex 
    Male 
    Female 
   Unknown 
 
307 / 55.4 
243 / 43.8 
4 / 0.7 
Referral 
   Western Cape 
   Out of Province (incl. international)  
   Unknown 
 
404 / 72.9 
145 / 26.1 
5 / 0.9 
Tumour location 
    Supratentorial 
    Infratentorial 
    Unknown 
 
288 / 52.0 
259 / 46.8 




Figure 3 summarises the gender distribution of the population. We found in this 
study that the overall male-to-female ratio was 1.26:1, consistent with the 
international published experience. 
 
The male predominance held true over most histological tumour types with the 
exceptions being (M:F) JPAs (0.92:1), DIPGs (0.89:1), choroid plexus tumours 
(0.89:1) and optic pathway gliomas (0.83:1) as shown in Figure 4. It is likely 
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that tumours captured as optic pathway gliomas were treated as such without 
histological diagnosis. 
 





































omas DIPG GBM ATRT
Choroid
plexus Pineal OPG
Male 58 35 33 32 14 24 9 9 8 11 5





















Figure 5 demonstrates some of the most common histological tumour types 
plotted against age of diagnosis.  
Unsurprisingly, the median ages of diagnosis for ATRT and choroid plexus 
tumours were younger, 0.92 years and 1.5 years respectively.  
FIGURE 5: Box plots of histological tumour types against age of 
diagnosis 
Anatomical location 
Figure 6 illustrates the tumour distribution by anatomical location: 
supratentorial tumours comprised 52%, infratentorial 47% and unknown 
location in 1%.  This was somewhat different to most reports, where 
infratentorial tumours are more common in children compared to their adult 
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counterparts. Some literature and textbook sources quote a ratio as high as 
60:40 for infratentorial vs supratentorial tumours. This is discussed in chapter 
5.  
FIGURE 6: Tumour distribution by anatomical location 











































































Figure 8 summarizes the most common tumour types diagnosed by histology 
or imaging characteristics over the study time period. The commonest tumours 
were astrocytomas (n=114 patients; 20.3%), followed by medulloblastomas 
(incl. PNETs) (n=107 patients; 19.1%), and craniopharyngiomas (n=55; 9.8%). 
 




Table 5 shows the median age of diagnosis, male-to-female ratio, and 
frequency of the most common tumours diagnosed. In keeping with most 
international literature there is a slight male-to-female (M:F) predominance. As 










































































































*PNET: Primitive neuroectodermal tumour; JPA: Juvenile Pilocytic Astrocytoma; DIPG: Diffuse infiltrating pontine 
glioma; GBM: Glioblastoma Multiforme; DNET: Dysembryoplastic neuroepithelial tumour; SEGA: Subependymal 
Giant Cell Astrocytoma; PXA: Pleomorphic Xanthoastrocytoma 
	 34	
TABLE 5: The most common paediatric brain tumours by diagnosis, 















6.25 5.5 7.25 4.71 5.42 0.92 
M:F 
 
1.26 : 1 1.29:1 1.18 : 1 1.5 : 1 
 
1.6 : 1 
 
0.89 : 1 
 




554 114 107 55 52 52 17 
 
*Astrocy: Astrocytomas / Medullos/PNET: Medulloblastomas, incl PNET / Cranio: Craniopharyngioma / ATRT: 
Atypical Teratoid Rhabdoid Tumour / Dx: diagnosis / mo: months  
 
Astrocytomas by specific sub-type 
 




*JPA: Juvenile Pilocytic Astrocytoma / NOS: not otherwise specified / GBM: Glioblastoma multiforme / SEGA: subependymal 























Figure 10 shows the number of cases diagnosed for each year. 





































































The epidemiology of paediatric brain tumours has been widely studied in the 
developed countries with high quality national registries existing in high income 
countries (HICs), but little comparison can be easily made with developing 
countries as much less data have been published.   
 
Information and research in general has increased exponentially over the last 
4 decades and despite this there is little information on the incidence and 
epidemiology of childhood brain tumours in South Africa, with inconsistent and 
slow transitioning into the digital era, gathering information on patients still 
remain a colossal and laborious task that yields unsatisfying results. Accurate 
electronic record keeping would be an important step towards developing and 
maintaining a national tumour data registry by allowing for the consolidation of 
information and contributing not only to better understanding of disease burden 
but also the available resources at each centre to treat specific conditions and 
diseases. 
 
The reported incidence of childhood brain tumours is 2-5 / 100 000 / year(2), 
and based on this figure approximately between 340-850 children with brain 
tumours should present annually in South Africa, based on updated population 
estimates from Statistics South Africa 2017 for children under the age of 14.  
RCCH and GSH paediatric neuro-oncology units are not the only centres in the 
Western Cape, let alone in South Africa to treat paediatric brain tumours, 
neither does it account for the public versus private sector division. 
Furthermore, provincial population statistics are in constant flux. Therefore no 
reasonable attempt could be made at accurately calculating the incidence or 
prevalence of paediatric brain tumours in South Africa or even in the Western 
Cape. The South African Children Tumour Registry (SACTR) was started in 
1987 to document the cancer burden of the national paediatric population. Data 
is collected by all the registered Peadiatric Oncology Units of South Africa on 
all maligancies of resident children in the Republic of South Africa under the 
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age of 18 years. This registry does not however include all types of paediatric 
brain tumours, only those that get referred to oncology units for treatment. This 
again stresses the importance of a paediatric brain tumour registry that can 





The unit receives referrals at both a provincial as well as national level, public 
and private, and occasionally extending beyond the borders of the country. 
 
As expected, most patients were from the Western Cape (73%), but still a 
significant percentage of referrals where from outside our drainage area both 
out of province and international referrals making up the remainder of the 
patients seen (26%). Over time, the proportion of patients referred from outside 
the province increased. In 1999, for example, 80% of the patients were from 
Western Cape (WC) and 20% were referred from outside the province. In 2016, 
by contrast, 46% were referred from outside the province. Most of the patients 
referred from outside of the Western Cape were from the private sector and the 
Eastern Cape.  
 
Possible reasons for increased referrals from outside of the province include 
the development of specialized services locally, increased awareness of the 




Sex distribution Consistent with most of the international literature, a slight 
male predominance was recorded in this study (M:F 1.26:1). This was similar 
to the results of Rickert and Paulus, in their meta-analysis of 10,582 childhood 
brain tumours, in which there was a M:F ratio of 1.29:1(15). 
 
Age It is unsurprising that ATRT and choroid plexus tumours were seen in 
younger children (median ages of 11 months and 18 months respectively), 
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whereas craniopharyngiomas were diagnosed in older children (median age of 
87 months) (Table 2, Chapter 2).  
 
It is clear though from both literature and this study that different tumour types 
affect different age groups and even within certain tumour subgroups, e.g. 
medulloblastomas the various molecular subtypes also present at different age 
ranges. We are unable, at this stage to compare this with our own dataset as 
molecular subtyping of medulloblastomas are is not routinely done in SA and 




This study found supratentorial tumours comprised 52% and infratentorial 47% 
(1% unknown). Infratentorial tumours are usually more common in the 
paediatric population compared to their adult counterparts: some sources quote 
a ratio as high as 60:40 for infratentorial vs supratentorial tumours.  Another 
study in Africa, conducted by El-Gaidi in Egypt, reported supratentorial tumours 
comprising 48% and infratentorial tumours 52%(16). A treatment-skewed bias 
may have influenced the distribution in the current study. It is possible that non-
specialist centres may be more comfortable managing standard cerebellar 
tumours, compared to more complex supratentorial tumours. In keeping with 
this, suprasellar tumours (especially craniopharyngiomas) were more likely to 
be referred from out of province in this series. It is also possible that patients 
with diffuse pontine gliomas who did not receive surgery (and therefore may 
not be captured in in the surgical database) and who did not receive 
radiotherapy may represent missing data of "unknown" patients. 
 
One of the difficulties in comparing tumour distribution by anatomical location 
is that definitions of anatomical locations for tumour types vary. Although some 
studies share the same basic categories of supratentorial vs infratentorial, 
many other studies use more complicated systems such as intrinsic vs extrinsic, 






Astrocytomas were the most common tumour (n=114 patients, 20.3%), 
followed by medulloblastomas (incl. PNETs) (n=107 patients, 19%), and 
craniopharyngiomas (n=55, 9.8%). Rickert and Paulus, in their meta-analysis 
of 10,582 childhood brain tumours accumulated from 16 international surveys 
showed some similarities: astrocytomas (37.6%), medulloblastomas (17.7%), 
ependymomas (9.9%), craniopharyngiomas (7.3%) and germ cell tumours 
(4.4%). Local differences might be explained by treatment options offered at 
our centre leading to a treatment-skewed bias of patients referred from the 
private sector or out of province. Not all tumours are equally managed in non-
specialist centres and there is likely a bias in patients who are referred. 
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TABLE 6: Comparison of common paediatric brain tumours between various series from different African countries(3) 
 
Study Ref Country Years of 
study 










1996-2017 554 6.3  0-17 1.26 288 259 114 107 52 55 N 
(3) Sudan 2000-2015 62 8.8 0-15 1.38 34 58 52 18 3 1.6 Y 
(17) Nigeria 1960-1982 89 NA 0-15 2.0 53 47 51.1 17.6 5.9 11.9 N 
(2) South 
Africa 
1979-1985 145 NA 0-14 1.16 47 53 24.8 26.2 10.3 8 N 
(18) Nigeria 1980-1990 75 NA 0-14 0.75 NA NA 40 10 NA 16 N 
(19) Tunisia 1990-2004 492 8 (median) 0-16 1.01 50.2 49.8 38 16.2 6.9 5.3 Y 
(20) Morocco 2003-2007 542 9.3 0-19 1.08 NA NA 31.6 28.9 10.3 6.6 N 
(16) Egypt 2005-2008 451 NA 0-14 1.06 46.6 49.7 35 18.8 10 11.3 N 
(21) Morocco 1991-2009 633 8.36 0-15 1.22 47 48 23.1 22.9 10.4 9 Y 
(22) Uganda 2002-2012 172 6.5 0-19 1.4 62.2 37.8 32.8 8.1 16.3 9.9 N 
(23) Nigeria 1994-2006 40 9.75 1-15 1.2 40 60 25 25 2.5 12.5 N 
 
n: number of patients / M:F Male:Female / ST: Supratentorial / IT: Infratentorial / AST: Astrocytoma / MED: Medulloblastoma / EPD: Epedymoma / CPG: 
Craniopharyngioma / SCT: Spinal Cord Tumours 
Challenges faced, limitations of the study and possible solutions 
 
Several challenges were faced in conducting this study. First, there is a lack of 
a standardised method for categorising, classifying and even describing the 
epidemiological data published on paediatric brain tumours, which creates 
inconsistency in how findings of different studies are reported and has made it 
difficult to compare and contrast findings. Attempting to draw comparisons for 
example of tumour type by anatomic location requires a standardised way of 
defining certain anatomic locations, e.g. infratentorial vs supratentorial 
locations.   
 
Second, the absence of a nationalised, or even institutional, paediatric brain 
tumour databank or registry has also highlighted the importance of this 
information not only to quantify the disease burden in the population but also to 
improve on referral to specialized, multi-disciplinary treatment centres, enabling 
better resource allocation for the specialized treatment of these patients and to 
minimise on patients lost to follow up by creating better documentation of 
patient treatment and progress. This has been recently addressed at our 
institution.  
 
Third, creating a complete dataset from retrospective collection is fraught with 
general limitations, as well as limitations specific to our hospitals. Some records 
were incomplete because of the hospital policy to destroy records that had been 
inactive over a certain period. For research, this has major implications for a 
study over a twenty year period. For clinical purposes, this is also a limitation 
because some patients are transferred to adult services but their original data 
are lost; thereby leading to discontinuity of care. Missing data from folders is 
also a limitation of paper-based records and highlights the need for transition 
to electronic data capture. This has occurred in both our radiology as well as 
histopathological services, but records prior to the transition (in 2012) were also 




Fourth, this study focussed on epidemiological data only, as a snapshot of the 
patients presenting to our service, and no attempt was made to analyse 
provision of services and clinical outcome. This will be the focus of a separate 
study. Limitations of follow up are expected to be a challenge also for these 




The findings in this were broadly consistent with published literature in terms of 
histological diagnosis, sex profile and age ranges for patients diagnosed with 
PBTs, with some differences thought to be possibly related to a referral bias. It 
documents the progressive increase in both the total number of cases 
diagnosed over the 22 year study period as well as in the number of patients 
seen from out of province referrals. The reported data and the limitations of the 
study emphasizes the importance of establishing an on-going tumour database 
registry for complete data capture of referred patients, their treatment, and their 
outcomes.  
Despite the challenges typical of retrospective hospital-based studies with 
missing or incomplete data, the study provides a valuable foundation on which 
to build a high quality prospective paediatric brain tumour registry. Not only will 
this stimulate ongoing research in this field, it will aid in establishing treatment 
modalities employed, identifying limits of the service, and determining success 
and failures in achieving desired clinical outcomes.  
RECOMMENDATIONS 
Continuation of high quality data registry and establishing an on-going 
prospective paediatric brain tumour registry for RCCH and GSH. 
Standardised classification to describe childhood brain tumours, especially by 
anatomical location. 
Cost analysis to assess feasibility of transitioning to electronic record keeping 
as is already done at some of the major tertiary hospitals in SA (Albert Lethuli 
Hospital in KZN and Tygerberg Hospital in the Western Cape). 
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WAY FORWARD 
The need for a follow up study to assess patient management and outcomes is 
of critical importance to assess effect of treatment modalities available and 
utilized and comparing outcomes and long-term survival for these group of 
patients. The second phase of data collection is already being planned and will 
commence as soon as appropriate ethical clearance has been obtained. 
Many factors, the most detrimental being the destruction of patient records, led 
to the study prioritising breath of data (i.e. making sure that as few patients as 
possible were missed) rather than depth of information. Therefore the second 
part of the study will be to focus on depth of information including data points 
as planned in the original study protocol, including presenting symptoms, 
investigations including specific imaging modalities used, treatment plans and 
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